BCL2 and B-cell non-Hodgkin lymphoma: In patients with bone marrow involvement, we also compared bone marrow involvement by MYC/BCL2 DHL (concordant) versus low-grade B-cell lymphoma (discordant) and there was no significant difference in OS (p = 0.24).